New combo therapy aims to boost esophageal cancer survival

NCT ID NCT07359443

First seen Jan 25, 2026 · Last updated May 10, 2026 · Updated 18 times

Summary

This early-phase trial tests adding a precise, MRI-guided radiation treatment after standard chemotherapy for people with esophageal adenocarcinoma. The goal is to find the highest safe radiation dose that can improve tumor control without causing severe side effects like fistulas or bleeding. About 39 adults with resectable tumors will receive five radiation sessions over two weeks, with doses increasing gradually in different groups. While the treatment may increase the chance of complete tumor response, it is not a cure and carries risks of serious complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, Utrecht, 3582CX, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.